An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa

Ki vehet részt

• Provision of signed and dated informed consent form
• Stated willingness to comply with all study procedures and availability for the duration of the study (Clinical interview)
• Aged 18-60 years (Clinical interview)
• Diagnosed with anorexia nervosa (EDA-5)
• BMI ≥ 15 kg/m2 (Clinical team medical record)

Ki nem vehet részt

• Antipsychotic medication (antidepressants at a stable dose are allowed) (clinical interview)
• Current diagnosis of schizophrenia, schizophreniform disorder, bipolar (type I), or substance use disorder (SCID)
• Diagnosis of chornic obstructive pulmonary disease (COPD) or Asthma (clinical interview) 9 Known allergic reactions to components of the donepezil (e.g., known hypersensitivity to donepezil hydrochloride) (clinical interview)
• History of peptic ulcer disease (clinical interview). 11. History of arrhythmia (clinical interview)
• Pregnancy (Serum pregnancy test on admission)
• Corrected QT interval (QTc) greater than 480 ms at baseline (EKG)
• Score of High Risk on the Columbia Suicide Severity Scale (C-SSRS)
• Bradycardia (below 60 bpm) (vital signs measurement by the clinical team)
• Citalopram treatment (clinical interview)